1. Home
  2. NBIX vs WY Comparison

NBIX vs WY Comparison

Compare NBIX & WY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurocrine Biosciences Inc.

NBIX

Neurocrine Biosciences Inc.

N/A

Current Price

$155.12

Market Cap

15.5B

Sector

Health Care

ML Signal

N/A

Logo Weyerhaeuser Company

WY

Weyerhaeuser Company

N/A

Current Price

$23.08

Market Cap

17.7B

Sector

Real Estate

ML Signal

N/A

Company Overview

Basic Information
Metric
NBIX
WY
Founded
1992
1900
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
15.5B
17.7B
IPO Year
1996
1994

Fundamental Metrics

Financial Performance
Metric
NBIX
WY
Price
$155.12
$23.08
Analyst Decision
Strong Buy
Buy
Analyst Count
22
7
Target Price
$180.91
$28.86
AVG Volume (30 Days)
1.1M
4.5M
Earning Date
05-05-2026
04-30-2026
Dividend Yield
N/A
3.46%
EPS Growth
41.95
N/A
EPS
3.30
0.44
Revenue
$161,626,000.00
$6,905,000,000.00
Revenue This Year
$24.73
$5.78
Revenue Next Year
$13.14
$8.94
P/E Ratio
$47.95
$52.65
Revenue Growth
977.51
N/A
52 Week Low
$122.14
$21.16
52 Week High
$186.12
$27.75

Technical Indicators

Market Signals
Indicator
NBIX
WY
Relative Strength Index (RSI) 48.44 36.31
Support Level $153.96 $22.54
Resistance Level $161.29 $25.14
Average True Range (ATR) 3.58 0.50
MACD 0.90 -0.16
Stochastic Oscillator 77.56 12.83

Price Performance

Historical Comparison
NBIX
WY

About NBIX Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

About WY Weyerhaeuser Company

Weyerhaeuser Co ranks among the world's key forest product companies. Following the 2016 sale of its pulp business to International Paper, Weyerhaeuser operates three business segments: timberlands, wood products, and real estate. Weyerhaeuser is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities. Earnings from its wood products segment are subject to federal income tax. Weyerhaeuser acquired fellow timber REIT Plum Creek in 2016.

Share on Social Networks: